££......Osmetech ......Smell the Success.....££

A couple of extracts from the early November trading update:

"The eSensor Cystic Fibrosis test is currently being reviewed by the FDA and
based upon the strong test data and other supporting information we anticipate
receiving approval either late this year or early next year."

"With the imminent launch of the OPTI LION and OPTI R products we expect a very
strong end to 2005 and start to 2006. This further underlines the excellent
progress with OPTI, taking it from a non-core, loss making enterprise when
acquired from Roche on attractive terms two years ago to one that is now a
profitable and cash generative growth business. For 2005 and 2006 we anticipate
that this continuing significant growth will exceed market expectations for
OPTI."